End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
19,934 ARS | +2.53% | +8.92% | +96.73% |
06-07 | Jefferies Adjusts Price Target on Eli Lilly to $957 From $925 | MT |
06-07 | US FDA Staff Flags Potential Limited Benefit of Eli Lilly's Alzheimer's Disease Drug | MT |
Sales 2024 * | 42.98B 38,639B 3,379B | Sales 2025 * | 52.62B 47,309B 4,137B | Capitalization | 765B 688,037B 60,172B |
---|---|---|---|---|---|
Net income 2024 * | 11.93B 10,727B 938B | Net income 2025 * | 16.55B 14,881B 1,301B | EV / Sales 2024 * | 18.2 x |
Net Debt 2024 * | 18.07B 16,245B 1,421B | Net Debt 2025 * | 15B 13,483B 1,179B | EV / Sales 2025 * | 14.8 x |
P/E ratio 2024 * |
63.6
x | P/E ratio 2025 * |
45.8
x | Employees | 43,000 |
Yield 2024 * |
0.61% | Yield 2025 * |
0.71% | Free-Float | 99.8% |
Latest transcript on Eli Lilly and Company
1 day | +2.53% | ||
1 week | +8.92% | ||
Current month | +8.92% | ||
1 month | +32.94% | ||
3 months | +39.88% | ||
6 months | +90.62% | ||
Current year | +96.73% |
Managers | Title | Age | Since |
---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 31/12/95 |
Ruth Gimeno
PSD | President | - | - |
David Hyman
CTO | Chief Tech/Sci/R&D Officer | - | 15/10/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 24/01/21 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 31/03/09 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 31/12/04 |
Date | Price | Change | Volume |
---|---|---|---|
07/06/24 | 19,934 | +2.53% | 4,023 |
06/06/24 | 19,442 | -0.19% | 2,815 |
05/06/24 | 19,479 | -0.29% | 2,614 |
04/06/24 | 19,536 | +1.62% | 4,409 |
03/06/24 | 19,226 | +5.05% | 4,346 |
End-of-day quote Buenos Aires S.E., June 06, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.16% | 354B | |
+19.86% | 331B | |
+9.32% | 299B | |
+18.81% | 248B | |
-0.98% | 219B | |
+11.25% | 216B | |
+5.90% | 164B | |
-0.73% | 162B | |
-0.53% | 123B |
- Stock Market
- Equities
- LLY Stock
- LLY Stock